Cell Therapies to Manufacture CAR-T Therapy for Phase 1/2b Solid Tumor Trial in Australia
The Australian CDMO will manufacture A-SEEDS' therapy for the upcoming trial down under.
Cancer
Replacing Magnetic Separation with Buoyancy: A Closer Look at Bracco’s New Cell Selection Platform, BubbleGen™
Could a gentler, more scalable method improve how cells are isolated for advanced therapies? We spoke with Bracco’s Sophie He about the early data, manufacturing potential, and challenges ahead.
Orca Bio Nabs FDA Approval of TREGZI, its Cell Therapy for Allogeneic Transplant in Adults with Blood Disorders
Following Phase 3, TREGZI, known as Orca-T, had higher graft-versus-host disease-free survival at one year in patients receiving conventional blood stem cell transplants.
Verismo Therapeutics to Use Cryoport’s IntegriCell® Cryopreservation Services in its Clinical KIR-CAR T Cell Therapy Programs
Verismo is ramping up its 2 Phase 1s targeting solid tumors and B-Cell non-Hodgkin lymphomas, selecting Cryoport for its cold chain.
CARsgen Nabs Chinese Approval of Satri-cel, its CAR-T Therapy for Stomach Cancer
Based on the RCT results published in The Lancet, the Chinese biotech company has received approval for the world's first CAR-T for solid tumors.
Specialised Therapeutics Nabs Australian Approval For Chronic Graft-Versus-Host Disease Therapy In Patients Receiving Blood Stem Cells
The therapy has been approved in the USA since 2024, and it'll soon be available down under as well, potentially reimbursed by Australia's pharma subsidy program.
Catalent to Supply Cartherics With iPSC Line To Manufacture CAR-NK Cell Therapies In Expanded Agreement
Cartherics is developing multiple immune cell therapies for women's health, including its lead candidate, CTH-401, a CAR-NK therapy targeting ovarian cancer.
Immatics Testing Cellular Origins’ Automated Cell Therapy Manufacturing Platform for Immuno-Oncology Programs
The company is evaluating whether Cellular Origins’ Constellation automation platform can be used in selected Immatics manufacturing steps to improve consistency, efficiency, and scalability for next-generation cancer cell therapies.
Phase II Finds Umbilical Cord Blood Transplant With Pooled Stem Cell Product Shows 96% Survival and No Graft-Versus-Host Disease in Leukemia Patients
A phase 2 trial found that adding a lab-expanded stem cell product made from multiple pooled cord blood donors to a single cord blood transplant may broaden access to transplants for leukemia...
TBMC Opens GMP Facility in Zhubei, Taiwan for Cell, Gene, and mRNA Manufacturing
This marks Taiwan’s first GMP facility with mRNA and nucleic acid manufacturing capabilities to expand its CRDMO services and support advanced therapies from development through commercial production.
